FBD Biologics Limited, Subsidiary of Han Kang-KY, Announces Strategic MOU with Innovative Biologics (Shanghai) Co., Ltd.

1. Date of Event: 115/07/08

2. Counterparty to the Agreement or Commitment: Innovative Biologics (Shanghai) Co., Ltd.

3. Relationship with the Company: None

4. Effective and Termination Dates of the Agreement or Commitment (or Termination Date): None

5. Main Content (Not applicable for termination): Subsidiary FBD Biologics Limited has signed a Strategic Memorandum of Understanding (MOU) with Innovative Biologics (Shanghai) Co., Ltd.

Under the MOU, both parties will leverage their respective clinical-stage products and technology platforms to jointly conduct preclinical and translational research, aiming to explore combination therapy strategies for refractory solid tumors.

This collaboration will investigate the combined application of HCB101, a fusion protein in clinical development, with IN10018/ifebemtinib, a FAK inhibitor developed by Innovative Biologics, and OMTX705, a FAP-targeting antibody-drug conjugate (ADC).

6. Restrictive Clauses (Not applicable for termination): None

7. Commitments (Not applicable for termination): None

8. Other Important Agreed Terms (Not applicable for termination): None

9. Impact on the Company's Financials and Operations: This MOU serves to confirm mutual cooperation intentions and currently has no significant impact on the company's financials or operations. Future steps will be evaluated based on the outcomes of preclinical and translational research.

10. Specific Purpose: To support the future development strategy and long-term growth of the company's core products.

11. Other Matters to be Disclosed (If the subject of the event or resolution is a publicly listed company or above, this material information also qualifies as an event under Article 7, Clause 8 of the Enforcement Rules of the Securities and Exchange Act that significantly affects shareholders' rights or securities prices):

(1) This MOU is intended for exploratory preclinical and translational research. Any subsequent collaboration or development arrangements will depend on research outcomes and future mutual agreements, and will be disclosed and reported in accordance with applicable regulations.

(2) Investors should note that there are risks associated with this project, including uncertainty regarding future research results, final agreement terms, and progress of the collaboration.